Bristol-Myers Squibb Co.

BMY trades at a jaw-dropping P/E of 47.86, nearly double the pharmaceutical sector median, yet sits just 47.3 on the RSI—far from overbought territory. The $119.7B market cap commands a premium valuation despite being 5.95% below its 52-week high, suggesting the market is pricing in significant future growth or pipeline success rather than current earnings power. With only 1.59% short interest, there's minimal squeeze potential, but the rich multiple leaves little margin for disappointment on upcoming catalysts. This setup screams execution risk: the stock needs blockbuster drug approvals or revenue acceleration to justify current pricing.